Literature DB >> 33579958

Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions.

Helga Bergholtz1,2, Tonje G Lien1, David M Swanson3, Arnoldo Frigessi3,4, Maria Grazia Daidone5, Jörg Tost6, Fredrik Wärnberg7,8, Therese Sørlie9,10.   

Abstract

Ductal carcinoma in situ (DCIS) is a non-invasive type of breast cancer with highly variable potential of becoming invasive and affecting mortality. Currently, many patients with DCIS are overtreated due to the lack of specific biomarkers that distinguish low risk lesions from those with a higher risk of progression. In this study, we analyzed 57 pure DCIS and 313 invasive breast cancers (IBC) from different patients. Three levels of genomic data were obtained; gene expression, DNA methylation, and DNA copy number. We performed subtype stratified analyses and identified key differences between DCIS and IBC that suggest subtype specific progression. Prominent differences were found in tumors of the basal-like subtype: Basal-like DCIS were less proliferative and showed a higher degree of differentiation than basal-like IBC. Also, core basal tumors (characterized by high correlation to the basal-like centroid) were not identified amongst DCIS as opposed to IBC. At the copy number level, basal-like DCIS exhibited fewer copy number aberrations compared with basal-like IBC. An intriguing finding through analysis of the methylome was hypermethylation of multiple protocadherin genes in basal-like IBC compared with basal-like DCIS and normal tissue, possibly caused by long range epigenetic silencing. This points to silencing of cell adhesion-related genes specifically in IBC of the basal-like subtype. Our work confirms that subtype stratification is essential when studying progression from DCIS to IBC, and we provide evidence that basal-like DCIS show less aggressive characteristics and question the assumption that basal-like DCIS is a direct precursor of basal-like invasive breast cancer.

Year:  2020        PMID: 33579958     DOI: 10.1038/s41523-020-0167-x

Source DB:  PubMed          Journal:  NPJ Breast Cancer        ISSN: 2374-4677


  59 in total

1.  Detection of ductal carcinoma in situ in women undergoing screening mammography.

Authors:  Virginia L Ernster; Rachel Ballard-Barbash; William E Barlow; Yingye Zheng; Donald L Weaver; Gary Cutter; Bonnie C Yankaskas; Robert Rosenberg; Patricia A Carney; Karla Kerlikowske; Stephen H Taplin; Nicole Urban; Berta M Geller
Journal:  J Natl Cancer Inst       Date:  2002-10-16       Impact factor: 13.506

Review 2.  Ductal carcinoma in situ of the breast.

Authors:  Harold J Burstein; Kornelia Polyak; Julia S Wong; Susan C Lester; Carolyn M Kaelin
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

3.  Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study.

Authors:  Laura C Collins; Rulla M Tamimi; Heather J Baer; James L Connolly; Graham A Colditz; Stuart J Schnitt
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

4.  The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up.

Authors:  Melinda E Sanders; Peggy A Schuyler; William D Dupont; David L Page
Journal:  Cancer       Date:  2005-06-15       Impact factor: 6.860

Review 5.  Screening for breast cancer in 2018-what should we be doing today?

Authors:  J M Seely; T Alhassan
Journal:  Curr Oncol       Date:  2018-06-13       Impact factor: 3.677

6.  Precancerous and cancerous breast lesions during lifetime and at autopsy. A study of 83 women.

Authors:  M Nielsen; J Jensen; J Andersen
Journal:  Cancer       Date:  1984-08-15       Impact factor: 6.860

Review 7.  Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes.

Authors:  Beth A Virnig; Todd M Tuttle; Tatyana Shamliyan; Robert L Kane
Journal:  J Natl Cancer Inst       Date:  2010-01-13       Impact factor: 13.506

8.  Intraductal carcinoma of the breast: follow-up after biopsy only.

Authors:  D L Page; W D Dupont; L W Rogers; M Landenberger
Journal:  Cancer       Date:  1982-02-15       Impact factor: 6.860

9.  Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy.

Authors:  D L Page; W D Dupont; L W Rogers; R A Jensen; P A Schuyler
Journal:  Cancer       Date:  1995-10-01       Impact factor: 6.860

Review 10.  Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis.

Authors:  Kylie L Gorringe; Stephen B Fox
Journal:  Front Oncol       Date:  2017-10-23       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.